Mark Peterson

After a painful restructuring, industrial manufacturer NN, Inc. is now exploring a sale. Is this the final step in its transformation or a capitulation?

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

As John Lindsay retires, H&P anoints tech-savvy insider Trey Adams. A look at how this smooth transition secures a legacy of innovation.

As TD SYNNEX prepares its full-year report, the results will be a crucial test of its AI strategy and a key indicator for the entire IT ecosystem.

GoPro is turning user videos into a new revenue stream for the AI economy. Can this bold strategic shift save the company, or will it get lost in the ethical fog?

Inotiv partners with AI firm VUGENE, but this is no simple tech deal. It's a high-stakes move to compete in a market dominated by AI-powered giants.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

Brink's new $750M share repurchase is more than a financial move; it’s a bold declaration that its digital transformation is generating serious cash.

Lindsay Corp.'s massive irrigation project in MENA isn't just a sale; it's a strategic move in the high-stakes race to solve global food security.

The EU's landmark decision to ease rules on New Genomic Techniques opens a multi-billion dollar market, and ag-tech pioneer Cibus is ready to cash in.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.